Roche, PureTech team up to develop oral antisense oligonucleotides

The Roche Tower (Roche)

Roche has struck a deal with PureTech Health to develop oral antisense oligonucleotides. The pact gives Roche access to PureTech’s milk-derived exosome technology in return for up to $36 million (€31 million) in near-term payments and milestones that could top out above $1 billion.

PureTech licensed the exosome technology from 3P Biotechnologies last year to gain a way to orally deliver biologics, nucleic acids and complex small molecules. The exosomes are designed to encase drugs and protect them from the environment in the gastrointestinal tract, thereby enabling the oral delivery of non-orally bioavailable molecules. Other researchers have explored the use of exosomes for this task, but PureTech thinks its delivery vehicles are more stable than potential competitors.

Roche has bought into the idea. The Swiss pharma will hand over up to $36 million in upfront fees, early preclinical milestones and research payments to get the project going. As products based on the exosome platform progress, Roche could pay out as much as $1 billion in milestones.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The numbers reflect the early-stage nature of the work and the size of the opportunities it could lead to. Antisense oligonucleotides have started to realize their potential to treat a range of diseases by reducing, restoring or otherwise modifying the expression of proteins. But getting molecules to their target sites remains challenging. Sanofi and Ionis’ Kynamro became the first systemically delivered antisense oligonucleotide to win approval in 2016 but oral administration remains an aspiration.

With Roche on board, PureTech thinks it may be able to realize that aspiration.

“The expertise and resources that Roche is bringing to the collaboration will help us to potentially address one of the biggest challenges in oligonucleotide-based therapeutic development: oral administration of nucleic acids,” PureTech CEO Daphne Zohar said in a statement.

PureTech unveiled the Roche deal alongside news of internal structural changes. The Boston-based, London-listed company is hiving off its projects focused on the gut-brain axis into a separate division called Ariya.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.